Table 2 Comparison of outcomes between early infliximab induction and delayed infliximab induction groups
Characteristics | Early infliximab induction (n = 73) | Delayed infliximab induction (n = 44) | p value |
|---|---|---|---|
Duration of follow-up, months (IQR) | 32.0 (21.0–60.5) | 37.5 (33.5–57.25) | 0.021 |
Initial surgery, n (%) | 0.001 | ||
Seton drainage | 70 (95.9) | 33 (75.0) | 0.001 |
Fistulotomy | 2 (2.7) | 8 (18.2) | 0.011 |
RAF | 0 (0) | 2 (4.5) | 0.296 |
LIFT | 1 (1.4) | 1 (2.3) | 1.000 |
Medical treatment at last follow-up, n (%) | 0.761 | ||
Infliximab | 10 (13.7) | 3 (6.8) | 0.524 |
Immunomodulators | 33 (45.2) | 21 (47.7) | 0.979 |
5-ASA | 4 (5.5) | 3 (6.8) | 0.934 |
None | 26 (35.6) | 17 (38.6) | 0.743 |
Re-intervention, n (%) | 25 (34.2) | 11 (25.0) | 0.294 |
Fistula healing, n (%) | 45 (61.6) | 29 (65.9) | 0.643 |
Re-intervention-free healing rate, n (%) | 33 (45.2) | 24 (54.6) | 0.328 |